EU/3/10/808: Orphan designation for the treatment of graft-versus-host disease
Murine monoclonal antibody against CD26
Table of contents
Overview
On 26 November 2010, orphan designation (EU/3/10/808) was granted by the European Commission to ADIENNE S.r.l., Italy, for murine monoclonal antibody against CD26 for the treatment of graft-versus-host disease.
In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Key facts
Active substance |
Murine monoclonal antibody against CD26
|
Intended use |
Treatment of graft-versus-host disease
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/10/808
|
Date of designation |
26/11/2010
|
Sponsor |
ADIENNE S.r.l.S.U.
Via Galileo Galilei, 19 20867 Caponago (MB) Italy Tel. +39 02 4070 0445 Fax +39 02 9574 5179 E-mail: adienne@adienne.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: